Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity
Sponsor: Novo Nordisk A/S
Summary
This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in adults living with obesity. Participants will either get NNC6022-0004, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.
Official title: An NNC6022-0004 Single and Multiple Ascending Dose Study Investigating Safety, Tolerability, Pharmacokinetics, Food Effect and Target Engagement in Healthy Adults Including a Single Cohort in Adults Living With Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
128
Start Date
2026-07-06
Completion Date
2027-08-01
Last Updated
2026-07-09
Healthy Volunteers
Yes
Interventions
NNC6022-0004
Participants will receive single dose of NNC6022-0004 administered orally in capsule form.
Placebo
Participants will receive placebo matched to NNC6022-0004 administered orally in capsule form.
Locations (1)
ICON - location Groningen
Groningen, Netherlands